SCHEMBL3451587

SCHEMBL3451587

CC(C)c1ccc(-c2csc(NC3CCC(C(=O)O)CC3)n2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 6/20 0.52
ITGA2B P08514 6/20 0.52
RAB9A P51151 3/20 0.51
NPC1 O15118 2/20 0.51
ABL1 P00519 2/20 0.48
NPY5R Q15761 1/20 0.47
KDM4E B2RXH2 1/20 0.46
KCNQ1 P51787 1/20 0.44
LMNA P02545 3/20 0.43
MAPT P10636 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ALOX12 P18054 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
TRPA1 O75762 1/20 0.43
ALDH1A1 P00352 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MRE11 P49959 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3974279 0.85 RAB9A (0.54) ITGB3ITGA2BRAB9ANPC1ABL1
SCHEMBL3451669 0.84 NPC1 (0.67) ITGB3ITGA2BRAB9ANPC1NPY5R
SCHEMBL4252324 0.82 KDM4E (0.69) ITGB3ITGA2BRAB9ANPC1KDM4E
SCHEMBL1474528 0.78 RAB9A (0.60) ITGB3ITGA2BRAB9ANPC1NPY5R
SCHEMBL3458042 0.74 RAB9A (0.50) RAB9ANPC1ABL1KDM4ELMNA
SCHEMBL21516871 0.73 RAB9A (0.59) RAB9ANPC1ABL1LMNAMAPT
SCHEMBL1473691 0.73 RAB9A (0.69) ITGB3ITGA2BRAB9ANPC1KDM4E
SCHEMBL27575993 0.71 ITGB3 (0.54) ITGB3ITGA2BRAB9ANPC1KDM4E
SCHEMBL3451243 0.70 SMN1; SMN2 (0.49) RAB9ANPC1KDM4ELMNAMAPT
SCHEMBL3452587 0.70 ABL1 (0.47) RAB9ANPC1ABL1KCNQ1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820704-B2 Substituted heteroaryl derivatives, compositions, and methods of use TRANSTECH PHARMA, INC. (US) 2010-10-26 US disclosed
US-7820704-B2 Substituted heteroaryl derivatives, compositions, and methods of use TRANSTECH PHARMA, INC. (US) 2010-10-26 US disclosed
US-7820704-B2 Substituted heteroaryl derivatives, compositions, and methods of use TRANSTECH PHARMA, INC. (US) 2010-10-26 US disclosed
CN-1946703-A Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators TRANSTECH PHARMA INC (US) 2007-04-11 CN disclosed
EP-1753735-A1 SUBSTITUTED THIAZOLE AND PYRIMIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR MODULATORS Transtech Pharma, Inc. (US) 2007-02-21 EP disclosed
US-20050261294-A1 Substituted heteroaryl derivatives, compositions, and methods of use VTVX HOLDINGS I LLC 2005-11-24 US disclosed
WO-2005103022-A1 SUBSTITUTED THIAZOLE AND PYRIMIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR MODULATORS TRANSTECH PHARMA, INC. (US) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261294-A1 Substituted heteroaryl derivatives, compositions, and methods of use MC5R, MC3R, MC4R ITGB3 1281/4885ITGA2B 1854/4885RAB9A 1296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.